Published in final edited form as:

Org Biomol Chem. 2014 June 14; 12(22): 3567–3571. doi:10.1039/c4ob00511b.

An Intramolecular Cascade Cyclization of 2-Aryl Indoles: Efficient Methods for the Construction of 2,3-Functionalized Indolines and 3-Indolinones

Arun K. Ghosh and Zhi-Hua Chen

Department of Chemistry and Department of Medicinal Chemistry Purdue University, West Lafayette, IN 47907 (USA)

Arun K. Ghosh: akghosh@purdue.edu

Abstract

Efficient intramolecular *N/O*-nucleophilic cyclization of 2-aryl indoles has been developed to afford the corresponding 2-aza-3-oxaindolines and 3-indolinones in 80–95% yield. The methods provided convenient access to fused imidazo[1,2-*c*]oxazolidinone, oxazolidine, or tetrahydro -1,3-oxazine cores under mild conditions.

Functionalized indole rings are one of the most abundant and important heterocycles that occur ubiquitously in bioactive natural products, pharmaceuticals and agrochemicals.^[1,2] Consequently, practical and atom-economical modifications of the indole structure have long been a subject of immense interest in organic and medicinal chemistry.^[3–5] Among them, intramolecular C2-functionalization of indoles such as *C*-,^[6] *N*-,^[7] *O*-,^[8] and *S*-nucleophilic cyclizations^[9] have received much attention since they provide straightforward access to indolines with a fused-ring substructure (Scheme 1, *a*). However to date, these transformations mainly focused on indole-based substrates with a pendant nucleophile tethered at the C3 position. Intramolecular cyclization of indole with a nucleophile attached to the nitrogen atom to construct an *N*-fused indoline has rarely been reported.^[10] Moreover, *N*-fused indolines exist widely throughout nature and have considerable biological and pharmaceutical importance.^[11–12] Therefore, development of efficient synthetic methods toward the formation of *N*-fused indolines is important for their utility in medicinal and biological chemistry. In connection with our work on the design and synthesis of ligands to probe enzyme active site, we became interested in functionalized indole derivatives. Herein, we wish to present our studies on the cascade halogenation/intramolecular nucleophilic cyclization of 2-aryl indoles to construct 2-aza-3-oxa indolines and 3-indolinones (Scheme 1, *b*).

As indicated in Table 1, our studies commenced with the halogenation/cyclization of **5a**,^[13] a model substrate that possesses an NHBoc group as the pendant nucleophile. The potential

reactivity of indoles toward electrophilic halogenating reagents, such as *N*-bromosuccinimide (NBS) and *N*-chlorosuccinimide (NCS), might offer a starting point to identify suitable reaction conditions. Disappointingly, the reactions of **5a** with NBS in CCl₄ at 0 °C or 23 °C under argon both gave complex mixtures (entry 1) and no desired cyclization product was obtained. However, the hypothesized halogenation/cyclization can be carried out by employing NCS as an electrophilic reagent, producing an unprecedented polycyclic indoline **6a** in 41% yield. As shown, the indoline derivative contains the expected imidazolidine ring along with an unexpected fused oxazolidinone functionality (entry 2). The structure of **6a** was unambiguously established using ¹H, ¹³C, and 2D NMR spectra. Optimization of the reaction was next investigated by varying the solvent. The reaction yield increased to 53% when CH₂Cl₂ was used in comparison to CCl₄, toluene, or Et₂O (entries 2–5). Subsequently, reaction temperature, time and the amount of NCS were screened to improve the reaction efficiency (entries 6–9). The best result was obtained (91% yield) when the reaction was performed with 3 equiv of NCS at 0 °C under argon for 3.5 h (entry 7). It should be noted that only 3-chloroindole was observed upon treatment of **5a** with 1 equiv NCS.^[14] This observation showed that excess NCS was critical to initiate the cascade cyclization and hydrogen chloride might be generated in this process (pH = 2–3). Accordingly, we attempted to add bases such as NaHCO₃, KHCO₃, or K₂CO₃ to neutralize the presumed acid. However, no obvious improvement was obtained (entries 10–12), indicating that acidic or basic conditions had no apparent influence on the reaction. Additionally, we found that when the reaction was carried out in the presence of air, the yield of **6a** was substantially reduced (entry 13). Reactions described above with different conditions all gave polycyclic indoline **6a** as a single *cis* diastereoisomer (entries 2–13), demonstrating the high diastereoselectivity of this cascade reaction. Presumably, the reaction of **5a** with NCS first proceeded with the formation of 3-chloroindole **7**. It then undergoes a NCS-promoted intramolecular cyclization as shown in intermediate **8** with the extrusion of isobutene to provide the cyclization product **6a** (Scheme 2).

Under the optimized reaction conditions, the scope of this cascade chlorination/cyclization have been explored by varying substitutions. As summarized in Table 2, indole scaffolds possessing electron-donating (5-Me, 4-Me, 5,7- dimethyl, and 5-MeO) or halogen (5-Cl) substituents on the benzenoid ring were well-tolerated and excellent yields were obtained (81–95%, **6b–6f**). In contrast, highly deactivated indole bearing a strongly electron-withdrawing group (5-NO₂) failed to afford the desired cyclization product. Furthermore, indoles incorporating various methyl-substituted pendant nucleophiles (**5g** and **5h**) underwent the reaction to give products **6g** and **6h** in 86% and 84% yields, respectively. Substitution of the 2-phenyl ring with *p*-methyl or *p*-methoxy substituents (**5i** and **5j**) were also found to be suitable substrates for cyclizations, delivering products **6i** and **6j** in 95% and 93% yields, respectively.

A single-crystal X-ray analysis of compound **6e** further confirmed the structure of the halogenation/cyclization product (Figure 1).^[15] Of particular interest, these highly functionalized indoline products **6a–6j**, which possess a new and interesting fused heterocyclic skeleton in common, might have potential applications in biological and material studies.

We have also investigated the development of a parallel halogenation/cyclization of the indole substrates bearing an *O*-nucleophile at the N-1 position. Our initial attempt was the reaction of 2-phenylindole **9a**^[16] and NCS in CCl₄ at 0 °C under air (Table 3, entry 1). Interestingly, the cyclization proceeded smoothly to afford 3-indolinone **10a** in 50% yield instead of the anticipated C3 mono-chlorinated indole. The structure of **10a** was confirmed using ¹H, ¹³C, and 2D NMR spectra. Considering that the oxygen of the newly formed carbonyl group in **10a** might be originating from H₂O in air, we added 3 equiv H₂O in the reaction and obtained **10a** in 55% yield (entry 2). Optimization of the reaction conditions was then turned to screening of solvent and reaction temperature (entries 3–5). Performing the reaction in CH₂Cl₂ at 23 °C reduced the reaction time and increased the yield to 81% (entry 5). Furthermore, a survey of base additive along with H₂O was found to accelerate the reaction and improve the yield up to 94% (entries 6–8). This observation is in contrast to the *N*-nucleophilic cyclization described above in which a base additive was not essential.

We further examined a range of indoles with different substitutions. As it turned out, the substrates also underwent the *O*-nucleophilic cyclization under our optimized conditions (Table 4).^[17] Indoles bearing electron-donating substituents (5-Me, 4-Me, 7-Me, 5,7-dimethyl, and 5-OMe) on the benzenoid ring worked well, leading to formation of the cyclization products **10b–10f** in excellent yields (91–95%). When 7-methyl-substituted indole **9d** was used, product **10d** was obtained upon standard conditions. Interestingly, chlorination of the indole ring also occurred by increasing the amount of NCS (5 equiv) and prolonging the reaction time (24 h), affording **10d'** in 93% yield. The electronic nature of the substrate has a slight influence on the reactivity, as indoles **9g** and **9h** with an electron-withdrawing group (5-Cl and 5-NO₂) required longer reaction times and provided relatively lower yields (83% and 80%). The reaction of indoles **9i–9k** with different aryl groups and substitution at the C2 position including *p*-MeC₆H₄, *p*-MeOC₆H₄, and 1-naphthyl also proceeded effectively to furnish the desired products **10i–10k** in 82–93% yield. Furthermore, formation of a tetrahydro-1,3-oxazine instead of an oxazolidine in this *O*-nucleophilic cyclization was examined. Indole **9l** with an expanded nucleophile was well-tolerated for this reaction, producing the expected product **10l** in 80% yield. Other indoles **9m–9o** with different substituents (5-Me, 5,7-dimethyl, and 5-OMe) on the benzenoid ring were also suitable for cyclization. In contrast to the formation of oxazolidine (**10a**, **10b**, **10e**, and **10f**), the pattern with larger tethers was slightly less favored as **10l–10o** were obtained in relatively lower yields (80–87%). Single-crystal X-ray analysis of **10e** further confirmed the structure of the *O*-nucleophilic cyclization product (Figure 2).^[15] Overall, the described *O*-nucleophilic cyclization has proved to be efficient and economical in comparison to previous syntheses of 3-indolinone **10a** and its analog.^[9a]

In summary, we have developed a new cascade chlorination/cyclization of 2-aryl indoles bearing an *N*-nucleophile. A range of polycyclic indolines were prepared in 81–95% yield by this process that simultaneously generates a fused imidazo[1,2-*c*]oxazolidinone skeleton and incorporates two adjacent hetero-quaternary stereocenters. Furthermore, we developed an *O*-nucleophilic cyclization in which a number of tricyclic tetrahydrooxazolo[3,2-*a*]indoles and tetrahydro-1,3-oxazino[3,2-*a*]indoles were effectively assembled in 80–95% yield. Mild conditions and practical convenience of both reactions deem these methods to be

valuable synthetic tools. Further studies including mechanistic investigations and the potential bioactivity of these novel compounds are currently ongoing in our laboratory.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

Financial support by the National Institutes of Health is gratefully acknowledged.

Notes and references

1. a) d'Ischia, M.; Napolitano, A.; Pezzella, A. *Comprehensive Heterocyclic Chemistry III*. Vol. 3. Elsevier; Oxford: 2008. p. 353-388. b) Kawasaki T, Higuchi K. *Nat Prod Rep*. 2005; 22:761–793. [PubMed: 16311634]
2. Kochanowska-Karamyan AJ, Hamann MT. *Chem Rev*. 2010; 110:4489–4497. [PubMed: 20380420]
3. a) Joucla L, Djakovitch L. *Adv Synth Catal*. 2009; 351:673–714. b) Bandini M, Eichholzer A. *Angew Chem, Int Ed*. 2009; 48:9608–9644. and references cited therein.
4. a) Bartoli G, Bencivenni G, Dalpozzo R. *Chem Soc Rev*. 2010; 39:4449–4465. [PubMed: 20848039] b) Palmisano G, Penoni A, Sisti M, Tibiletti F, Tollari S, Nicholas KM. *Curr Org Chem*. 2010; 14:2409–2441. c) Cacchi S, Fabrizi G. *Chem Rev*. 2011; 111:pr215–283. [PubMed: 21557620] d) Platon M, Amardeil R, Djakovitch L, Hierso JC. *Chem Soc Rev*. 2012; 41:3929–3968. [PubMed: 22447100]
5. a) Inman M, Moody CJ. *Chem Sci*. 2013; 4:29–41. b) Gritsch PJ, Leitner C, Pfaffenbach M, Gaich T. *Angew Chem, Int Ed*. 2013; 53:1208–1217.
6. a) Trost B, Quancard J. *J Am Chem Soc*. 2006; 128:6314–6315. [PubMed: 16683785] b) Han B, Xiao YC, Yao Y, Chen YC. *Angew Chem, Int Ed*. 2010; 49:10189–10191.
7. For selected publications, see: Ikeda M, Tabusa F, Nishimura Y, Kwon S, Tamura Y. *Tetrahedron Lett*. 1976; 17:2347–2350. Zhu Y, Rawal VH. *J Am Chem Soc*. 2012; 134:111–114. [PubMed: 22133348] Xie W, Jiang G, Liu H, Hu J, Pan X, Zhang H, Wan X, Lai Y, Ma D. *Angew Chem, Int Ed*. 2013; 52:12924–12927.
8. For selected publications, see: Saito I, Imuta M, Matsugo S, Matsuura T. *J Am Chem Soc*. 1975; 97:7191–7193. Beaumont S, Pons V, Retailleau P, Dodd RH, Dauban P. *Angew Chem, Int Ed*. 2010; 49:1634–1637. Lin A, Yang J, Hashim M. *Org Lett*. 2013; 15:1950–1953. [PubMed: 23566252] Zhang X, Han L, You SL. *Chem Sci*. 2014; 5:1059–1063.
9. An-naka M, Yasuda K, Yamada M, Kawai A, Takamura N, Sugawara S, Matsuoka Y, Iwata H, Fukushima T. *Heterocycles*. 1994; 39:251–270.
10. a) Hewitt MC, Shao L. *ARKIVOC*. 2006; xi:37–46. b) Lozano O, Blessley G, Martinez del Campo T, Thompson AL, Giuffredi GT, Bettati M, Walker M, Borman R, Gouverneur V. *Angew Chem, Int Ed*. 2011; 50:8105–8109. c) Lin R, Ding S, Shi Z, Jiao N. *Org Lett*. 2011; 13:4498–4501. [PubMed: 21827141] d) Nguyen TM, Duong HA, Richard JA, Johannes CW, Pincheng F, Ye DKJ, Shuying EL. *Chem Commun*. 2013; 49:10602–10604.
11. a) Ewing J, Hughes GK, Ritchie E, Taylor WC. *Nature*. 1952; 169:618–619. b) Hata T, Sano Y, Sugawara R, Matsumae A, Kanamori K, Shima T, Hoshi T. *J Antibiot Ser A*. 1956; 9:141–146. c) Goldbrunner M, Loidl G, Polossek T, Mannschreck A, Angerer EV. *J Med Chem*. 1997; 40:3524–3533. [PubMed: 9357519] d) Bös M, Jenck F, Martin JR, Moreau JL, Mutel V, Sleight AJ, Widmer U. *Eur J Med Chem*. 1997; 32:253–261.
12. a) Jiao RH, Xu S, Liu JY, Ge HM, Ding H, Xu C, Zhu HL, Tan RX. *Org Lett*. 2006; 8:5709–5712. [PubMed: 17134253] b) Ames BD, Liu X, Walsh CT. *Biochemistry*. 2010; 49:8564–8576. [PubMed: 20804163] c) Cai S, Du L, Gereia AL, King JB, You J, Cichewicz RH. *Org Lett*. 2013; 15:4186–4189. [PubMed: 23924243]
13. For the preparation of indoles 5a–5j, please see the supporting information.

14. a) Higa T, Scheuer PJ. *Heterocycles*. 1976; 4:231–233. b) Wang Z, Vince R. *Bioorg Med Chem*. 2008; 16:3587–3595. [PubMed: 18314335]
15. CCDC 982161 (6e) and 983003 (10e) contain supplementary crystallographic data for this paper. These data could be obtained free of charge from The Cambridge Crystallographic Data Centre via www.ccdc.cam.ac.uk/data_request/cif.
16. Ding H, Zhang C, Wu X, Yang C, Zhang X, Ding J, Xie Y. *Bioorg Med Chem Lett*. 2005; 15:4799–4802. [PubMed: 16143526]
17. For the preparation of indoles 9b–9o, please see the supporting information.

Figure 1.
X-ray structure of **6e**.

Figure 2.
X-ray structure of **10e**.

- a) Well-developed intramolecular cyclization of indoles:
nucleophile tethered to C-3 position

- b) This work: nucleophile tethered to the nitrogen of indoles

Scheme 1.

Intramolecular nucleophilic cyclization of indoles.

Scheme 2. Intramolecular cascade cyclization of 2-aryl indole **5a**.

Table 1

Validation and optimization of the *N*-nucleophilic cyclization.^[a]

Entry	Halogenating reagent	Solvent	Temp (°C)	Time (h)	Base	Yield (%) ^[b]
1	NBS (2 eq)	CCl ₄	0/23	1	–	–
2	NCS (2 eq)	CCl ₄	23	2	–	41
3	NCS (2 eq)	toluene	23	2	–	46
4	NCS (2 eq)	CH ₂ Cl ₂	23	2	–	53
5	NCS (2 eq)	Et ₂ O	23	24	–	10
6	NCS (2 eq)	CH ₂ Cl ₂	0	7	–	73
7	NCS (3 eq)	CH ₂ Cl ₂	0	3.5	–	91
8	NCS (3 eq)	CH ₂ Cl ₂	–10	24	–	85
9	NCS (4 eq)	CH ₂ Cl ₂	0	2	–	65
10 ^[c]	NCS (3 eq)	CH ₂ Cl ₂	0	3.5	NaHCO ₃	90
11 ^[c,d]	NCS (3 eq)	CH ₂ Cl ₂	0	3.5	KHCO ₃	88
12 ^[c]	NCS (3 eq)	CH ₂ Cl ₂	0	3.5	K ₂ CO ₃	91
13 ^[d]	NCS (3 eq)	CH ₂ Cl ₂	0	3.5	–	71

^[a] All reactions were performed with 0.2 mmol of **5a** in 2 mL of solvent under argon.

^[b] Isolated yield.

^[c] 3 equiv of base.

^[d] Reaction performed under air. NBS = *N*-bromosuccinimide, NCS = *N*-chlorosuccinimide.

Table 2

Substrate scope of the *N*-nucleophilic cyclization.^[a]

^[a] Substrate **5** (0.2 mmol) was dissolved in freshly distilled CH₂Cl₂ (2 mL) at 0 °C under argon followed by addition of NCS (0.6 mmol).

^[b] The ratio of diastereoisomers was determined by ¹H NMR. NCS = *N*-chlorosuccinimide.

Table 3

Validation and optimization of the *O*-nucleophilic cyclization.^[a]

Entry	Halogenating reagent	Solvent	Temp (°C)	Time (h)	Additive ^[b]	Yield (%) ^[c]
1	NCS (2 eq)	CCl ₄	0	15	–	50
2	NCS (2 eq)	CCl ₄	0	15	H ₂ O	55
3	NCS (2 eq)	toluene	0	17	H ₂ O	48
4	NCS (2 eq)	CH ₂ Cl ₂	0	12	H ₂ O	65
5	NCS (2 eq)	CH ₂ Cl ₂	23	7	H ₂ O	81
6	NCS (2 eq)	CH ₂ Cl ₂	23	5	H ₂ O/K ₂ CO ₃	85
7	NCS (2 eq)	CH ₂ Cl ₂	23	5	H ₂ O/KHCO ₃	90
8	NCS (2 eq)	CH ₂ Cl ₂	23	5	H ₂ O/NaHCO ₃	94

^[a] All reactions were performed with 0.2 mmol of **9a** in 2 mL of solvent under air.

^[b] 3 equiv of H₂O and base.

^[c] Isolated yield. NCS = *N*-chlorosuccinimide.

Table 4

Substrate scope of the *O*-nucleophilic cyclization.^[a]

^[a] Substrate **9** (0.2 mmol) was dissolved in freshly distilled CH₂Cl₂ (2 mL) at 23 °C under air followed by addition of NaHCO₃ (0.6 mmol), H₂O (0.6 mmol), and NCS (0.4 mmol).

^[b] Treatment of **9d** (0.2 mmol) with NaHCO₃ (1.5 mmol), H₂O (1.5 mmol), and NCS (1.0 mmol) in freshly distilled CH₂Cl₂ (3 mL) at 23 °C under air for 24 h. NCS = *N*-chlorosuccinimide.